Semaglutide linked to 21% drop in bipolar psychiatric hospital stays
A Swedish cohort study found that patients with bipolar disorder using semaglutide (Ozempic or Wegovy) experienced a 21% lower risk of psychiatric hospitalization.
A large Swedish registry analysis covering 15,000 individuals with bipolar disorder investigated the impact of glucagon-like peptide-1 receptor agonists on mental health outcomes. Participants taking semaglutide, marketed as Ozempic or Wegovy, had a 21% lower likelihood of being hospitalized for psychiatric reasons compared with periods when they were not on the medication. No comparable benefit was observed for other GLP-1 drugs such as liraglutide or dulaglutide.
The authors propose that semaglutide’s influence on inflammatory and cellular stress mechanisms in the brain may underlie the observed mood-stabilizing effect. The study, led by Professor Mark Taylor at Griffith University, appears in Acta Psychiatrica Scandinavica and highlights the need for controlled trials to establish causality. If confirmed, semaglutide could represent a novel adjunctive treatment for bipolar disorder.
Why it matters
The result suggests a widely used diabetes drug might also help reduce severe bipolar episodes, offering a new therapeutic avenue.
In this story
